Percheron Therapeutics Limited - PER share price

About

Percheron Therapeutics Limited, formerly known as Antisense Therapeutics Limited, operates as a biotechnology company with a focus on the development and commercialization of antisense pharmaceuticals catering to significant unmet needs in the realm of rare diseases. The company's product portfolio includes ATL1102, designed for Duchenne muscular dystrophy (DMD), ATL1103 for Acromegaly, and ATL1102 for Multiple Sclerosis (MS). ATL1102 acts as an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. Meanwhile, ATL1103, a second-generation antisense drug, is crafted to impede the expression of the growth hormone receptor (GHr), thereby decreasing levels of the hormone insulin-like growth factor-I (IGF-I) in the bloodstream. This drug holds promise as a potential treatment for conditions linked to excessive growth hormone activity. Through the suppression of GHr production, ATL1103 effectively lowers IGF-I levels in the blood (serum). The company is actively involved in a Phase II clinical trial of ATL1102 for DMD patients.